Elekta AB (publ) (LON:0O5H)
London · Delayed Price · Currency is GBP · Price in SEK | Market Cap | 1.39B -1.6% |
| Revenue (ttm) | 1.33B -7.2% |
| Net Income | -41.28M |
| EPS | -0.11 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 11.42 |
| Dividend | 0.19 (5.33%) |
| Ex-Dividend Date | Mar 5, 2026 |
| Volume | 95,357 |
| Open | 47.43 |
| Previous Close | 47.82 |
| Day's Range | 46.76 - 47.62 |
| 52-Week Range | 42.20 - 66.60 |
| Beta | 0.96 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 3, 2026 |
About Elekta AB
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear machines and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo, a CT-Linac solution; Elekta Versa HD, a brain metastases solution; Elekta Harmony; and Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs, as well as quality assurance, and treatment and ... [Read more]
News
Elekta price target lowered to SEK 52 from SEK 60 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Elekta (EKTAY) to SEK 52 from SEK 60 and keeps a Hold rating on the shares.
Elekta AB Transcript: CMD 2026
Management outlined a turnaround strategy focused on innovation, operational excellence, and regional growth, targeting mid-single digit revenue CAGR and 14%-16% EBIT margin by 2028/2029. Key levers include adaptive radiotherapy, software/service expansion, and disciplined commercial execution, with strong positions in Europe, the U.S., and China.
Elekta AB Press release: FY 2026
Elekta AB issued a press release on June 17, 2026, disclosing material business information to investors.
Elekta AB Slides: FY 2026
Elekta AB has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 17, 2026.
Elekta downgraded to Hold from Buy at SEB Equities
SEB Equities analyst Mattias Vadsten downgraded Elekta (EKTAY) to Hold from Buy with a SEK 58 price target
Elekta AB Transcript: Q4 25/26
Transformation and cost-saving initiatives drove improved profitability, with EBITDA margin at a seven-year high and net debt reduced. Stricter order criteria and a SEK 1.4 billion impairment improved earnings quality, while outlook remains positive with further margin gains expected.
Elekta AB Quarterly report: Q4 2026
Elekta AB has published its Q4 2026 quarterly earnings report on May 28, 2026.
Elekta AB Slides: Q4 2026
Elekta AB has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 28, 2026.
Elekta AB Annual report: Q4 2026
Elekta AB has published its Q4 2026 annual report on May 28, 2026.
Elekta downgraded to Sell from Hold at Danske Bank
Danske Bank analyst Erik Cassel downgraded Elekta (EKTAY) to Sell from Hold with a SEK 45 price target
Elekta price target raised to SEK 60 from SEK 49 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Elekta (EKTAY) to SEK 60 from SEK 49 and keeps a Hold rating on the shares.
Elekta AB Transcript: Q3 25/26
Solid Q3 performance with improved margins and strong order growth in China and the U.S., despite FX and tariff headwinds. Restructuring is nearly complete, with over SEK 500 million in annual savings expected from Q1 next year.
Elekta AB Quarterly report: Q3 2026
Elekta AB has published its Q3 2026 quarterly earnings report on March 5, 2026.
Elekta AB Slides: Q3 2026
Elekta AB has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on March 5, 2026.
Elekta AB Transcript: Strategy update
Four strategic priorities are driving transformation: operational simplification, focused innovation, regional growth in China and the US, and ongoing cost reduction. Decentralization, new leadership, and a shift to faster, customer-driven innovation cycles are underway, with significant savings and market share gains expected.
Elekta AB Press release: Strategy update
Elekta AB issued a press release on January 30, 2026, disclosing material business information to investors.
Elekta AB Slides: Strategy update
Elekta AB has posted slides in relation to its latest quarterly earnings report, which was published on January 30, 2026.
Elekta price target lowered to SEK 52 from SEK 61 at JPMorgan
JPMorgan analyst David Adlington lowered the firm’s price target on Elekta (EKTAY) to SEK 52 from SEK 61 and keeps an Underweight rating on the shares.
Elekta AB Transcript: Q2 25/26
Q2 saw modest organic growth, margin improvement, and strong cash flow, with Europe leading performance and China showing order recovery. A new operating model and 10% workforce reduction target SEK 500 million in cost savings, while order backlog was cleaned up with no revenue impact.
Elekta AB Quarterly report: Q2 2026
Elekta AB has published its Q2 2026 quarterly earnings report on November 26, 2025.
Elekta AB Slides: Q2 2026
Elekta AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 26, 2025.
Elekta initiated with a Sell at UBS
UBS analyst Kavya Deshpande initiated coverage of Elekta (EKTAY) with a Sell rating and SEK 34 price target The firm’s analysis suggests the radiotherapy market is slowing meaningfully and that…
Elekta price target lowered to SEK 48 from SEK 49.50 at Barclays
Barclays lowered the firm’s price target on Elekta (EKTAY) to SEK 48 from SEK 49.50 and keeps an Underweight rating on the shares.
Elekta AB Transcript: Q1 25/26
Q1 saw 3% sales growth in constant currency, led by strong EMEA performance and new product launches, but margins declined due to FX and tariffs. U.S. and China remain weak, with recovery in China expected in H2, and full-year sales growth guidance is reiterated.
Elekta AB Quarterly report: Q1 2026
Elekta AB has published its Q1 2026 quarterly earnings report on August 28, 2025.